Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Centre Hospitalier Universitaire De Lille currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, showing that every pending matter is being reviewed by a different official. The workload is spread across 3 distinct art units, which suggests technical variety within the company's pharmaceutical interests. This distribution requires the applicant to monitor different examination styles simultaneously while maintaining a consistent overall strategy for the portfolio.
ALDARONDO, DASIA ALI is identified as the busiest examiner for this portfolio. This examiner is currently handling 1 busiest examiner pending office action. The remaining actions are distributed among the other examiners. This distribution across multiple examiners and 3 distinct art units may require the applicant to coordinate different prosecution strategies. Practitioners should be prepared to address the specific concerns of separate officials, even though the technical focus remains within the pharmaceutical field. The presence of multiple art units indicates that the company's applications are classified under different categories, each with its own set of prior art and examination standards.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
| AUGER, NOAH ANDREW | 1 | 36.2% | +42.6% |
| HELM, CARALYNNE E | 1 | 28.9% | +49.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18689994 | CORONAVIRUS FUSION PROTEIN | ALDARONDO, DASIA ALI | — |
| 18262440 | METHOD TO DIAGNOSE MSI CANCER | AUGER, NOAH ANDREW | — |
| 18256719 | PHARMACEUTICAL COMPOSITION CONTAINING PROPOFOL, A CYCLODEXTRIN OR A CYCLODEXTRIN DERIVATIVE AND A PHARMACEUTICALLY ACCEPTABLE SALT | HELM, CARALYNNE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262440 | METHOD TO DIAGNOSE MSI CANCER | AUGER, NOAH ANDREW | — |
| 18256719 | PHARMACEUTICAL COMPOSITION CONTAINING PROPOFOL, A CYCLODEXTRIN OR A CYCLODEXTRIN DERIVATIVE AND A PHARMACEUTICALLY ACCEPTABLE SALT | HELM, CARALYNNE E | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1687 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18689994 | CORONAVIRUS FUSION PROTEIN | ALDARONDO, DASIA ALI | 1647 | §102§112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18262440 | METHOD TO DIAGNOSE MSI CANCER | AUGER, NOAH ANDREW | 1687 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 21, 2023 |
| 18256719 | PHARMACEUTICAL COMPOSITION CONTAINING PROPOFOL, A CYCLODEXTRIN OR A CYCLODEXTRIN DERIVATIVE AND A PHARMACEUTICALLY ACCEPTABLE SALT | HELM, CARALYNNE E | 1615 | §103§112 | Final Rejection | — | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentre Hospitalier Universitaire De Lille has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Dasia Ali Aldarondo has the most, with 1 of Centre Hospitalier Universitaire De Lille's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
